1
|
Zheng H, Chen K, Dun Y, Xu Y, Zhou A, Ge H, Yang Y, Ning X. Harnessing Nature's ingenuity to engineer butterfly-wing-inspired photoactive nanofiber patches for advanced postoperative tumor treatment. Biomaterials 2025; 314:122808. [PMID: 39270626 DOI: 10.1016/j.biomaterials.2024.122808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2024] [Revised: 08/21/2024] [Accepted: 09/01/2024] [Indexed: 09/15/2024]
Abstract
Postoperative tumor treatment necessitates a delicate balance between eliminating residual tumor cells and promoting surgical wound healing. Addressing this challenge, we harness the innovation and elegance of nature's ingenuity to develop a butterfly-wing-inspired photoactive nanofiber patch (WingPatch), aimed at advancing postoperative care. WingPatch is fabricated using a sophisticated combination of electrostatic spinning and spraying techniques, incorporating black rice powder (BRP) and konjac glucomannan (KGM) into a corn-derived polylactic acid (PLA) nanofiber matrix. This fabrication process yields a paclitaxel-infused porous nanofiber architecture that mirrors the delicate patterns of butterfly wings. Meanwhile, all-natural composites have been selected for their strategic roles in postoperative recovery. BRP offers the dual benefits of photothermal therapy and antibacterial properties, while KGM enhances both antibacterial effectiveness and tissue regeneration. Responsive to near-infrared light, WingPatch ensures robust tissue adhesion and initiates combined photothermal and chemotherapeutic actions to effectively destroy residual tumor cells. Crucially, it simultaneously prevents infections and promotes wound healing throughout the treatment process. Its effectiveness has been confirmed by animal studies, and WingPatch significantly improves treatment outcomes in both breast and liver tumor models. Thus, WingPatch exemplifies our dedication to leveraging natural world's intricate patterns and inventiveness to propel postoperative care forward.
Collapse
Affiliation(s)
- Hao Zheng
- National Laboratory of Solid State Microstructures, Collaborative Innovation Center of Advanced Microstructures, Chemistry and Biomedicine Innovation Center, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, 210093, China
| | - Kerong Chen
- National Laboratory of Solid State Microstructures, Collaborative Innovation Center of Advanced Microstructures, Chemistry and Biomedicine Innovation Center, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, 210093, China
| | - Yitong Dun
- International Department of Jinling High School Hexi Campus, Nanjing, 210019, China
| | - Yurui Xu
- National Laboratory of Solid State Microstructures, Collaborative Innovation Center of Advanced Microstructures, Chemistry and Biomedicine Innovation Center, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, 210093, China
| | - Anwei Zhou
- National Laboratory of Solid State Microstructures, Collaborative Innovation Center of Advanced Microstructures, Chemistry and Biomedicine Innovation Center, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, 210093, China.
| | - Haixiong Ge
- National Laboratory of Solid State Microstructures, Collaborative Innovation Center of Advanced Microstructures, Chemistry and Biomedicine Innovation Center, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, 210093, China.
| | - Youwen Yang
- Jiangxi Province Key Laboratory of Additive Manufacturing of Implantable Medical Device, Jiangxi University of Science and Technology, Nanchang, 330013, China.
| | - Xinghai Ning
- National Laboratory of Solid State Microstructures, Collaborative Innovation Center of Advanced Microstructures, Chemistry and Biomedicine Innovation Center, College of Engineering and Applied Sciences, Jiangsu Key Laboratory of Artificial Functional Materials, Nanjing University, Nanjing, 210093, China.
| |
Collapse
|
2
|
Shen J, Feng K, Yu J, Zhao Y, Chen R, Xiong H, Ruan Y, Xu Z, Zhang T, Sun X. Responsive and traceless assembly of iron nanoparticles and 131I labeled radiopharmaceuticals for ferroptosis enhanced radio-immunotherapy. Biomaterials 2025; 313:122795. [PMID: 39232333 DOI: 10.1016/j.biomaterials.2024.122795] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2024] [Revised: 08/07/2024] [Accepted: 08/30/2024] [Indexed: 09/06/2024]
Abstract
Ferroptosis is an iron-dependent form of programmed cell death with the potential to reverse traditional cancer therapy resistance. The combination of ferroptosis with chemotherapy, photodynamic therapy and X-ray therapy has demonstrated remarkably improved therapeutic efficiency. Radiopharmaceutical therapy (RPT) is an emerging approach that achieves precise radiation to diseased tissues via radionuclide delivery. However, insufficient accumulation and retention of therapeutic radiopharmaceuticals in tumor region as well as cancer radioresistance impact treatment efficacy. Here, a nanoassembly of renal clearable ultrasmall iron nanoparticles (USINPs) and 131I-aPD-L1 is prepared via the affinity of fluorophenylboronic acid modified on the USINPs with 131I-aPD-L1. The 150 nm USINAs(131I-aPD-L1) nanoassembly is stable in blood circulation, effectively targets to the tumor and disassembles in the presence of ATP in the tumor microenvironment. Both in vitro and in vivo experiments prove that USINPs-induced ferroptosis boosted the tumor radiosensitization to 131I while 131I-mediated RPT further enhanced ferroptosis. Meanwhile, the immunogenic cell death caused by RPT and ferroptosis combined with PD-L1 immune checkpoint blockade therapy exhibits a strong antitumor immunity. This study provides a novel way to improve the tumor accumulation of ferroptosis inducer and radiopharmaceuticals, insights into the interaction between RPT and ferroptosis and an effective SPECT-guided ferroptosis-enhanced radio-immunotherapy.
Collapse
Affiliation(s)
- Jingjing Shen
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Kai Feng
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Jing Yu
- College of Materials Science and Engineering, Research Center of Magnetic and Electronic Materials, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Yaxuan Zhao
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Ruifang Chen
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Hehua Xiong
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Yiling Ruan
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China
| | - Zhengtao Xu
- College of Materials Science and Engineering, Research Center of Magnetic and Electronic Materials, Zhejiang University of Technology, Hangzhou, 310014, China
| | - Tao Zhang
- Northern Jiangsu Institute of Clinical Medicine, Department of Radiopharmaceuticals, Nuclear Medicine Clinical Translation Center, School of Pharmacy, Nanjing Medical University, Nanjing, 211166, China.
| | - Xiaolian Sun
- State Key Laboratory of Natural Medicines, Key Laboratory of Drug Quality Control and Pharmacovigilance, School of Pharmacy, China Pharmaceutical University, Nanjing, 210009, China.
| |
Collapse
|
3
|
Sun N, Wang T, Zhang S. Radionuclide-labelled nanoparticles for cancer combination therapy: a review. J Nanobiotechnology 2024; 22:728. [PMID: 39578828 PMCID: PMC11585169 DOI: 10.1186/s12951-024-03020-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2024] [Accepted: 11/14/2024] [Indexed: 11/24/2024] Open
Abstract
Radionuclide therapy (RT) is widely used to advanced local cancers. However, its therapeutic efficacy is limited to the radiation resistance of cancer cells. Combination therapy aims to circumvent tumor resistance, and the combination of RT with photothermal therapy (PTT), photodynamic therapy (PDT), chemotherapy (CMT), and immunotherapy has shown promising treatment outcomes. Nanotechnology holds promise in advancing combination therapy by integrating multiple therapies on a nanostructure platform. This is due to the increased surface area, passive/active targeting capabilities, high payload capacity, and enriched surface of nanomedicines, offering significant advantages in treatment sensitivity and specificity. In the first part of this review, we categorize radionuclide therapy. The second part summarizes the latest developments in combination therapies, specifically focusing on the integration of RT with PTT, PDT, CMT and immunotherapy. The last part provides an overview of the challenges and potential opportunities related to radionuclide-labelled nanoparticles for cancer combination therapy.
Collapse
Affiliation(s)
- Na Sun
- Department of Nuclear Medicine, XinQiao Hospital, Army Medical University, ChongQing, 400037, China
| | - Tao Wang
- Department of Nuclear Medicine, XinQiao Hospital, Army Medical University, ChongQing, 400037, China
| | - Song Zhang
- Department of Nuclear Medicine, XinQiao Hospital, Army Medical University, ChongQing, 400037, China.
| |
Collapse
|
4
|
Munekane M, Ozaki M, Mitani Y, Sakaida N, Sano K, Yamasaki T, Mukai T, Mishiro K, Fuchigami T, Ogawa K. Development of Radiolabeled Probes with Improved Imaging Contrast by Releasing Urinary Excretable Radiolabeled Compounds from Thermosensitive Liposomes in the Blood. Mol Pharm 2024; 21:5728-5735. [PMID: 39445871 DOI: 10.1021/acs.molpharmaceut.4c00732] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2024]
Abstract
In this study, thermosensitive liposomes (TSLs) encapsulating urinary excretable radiolabeled compounds were developed. We considered that the release of the radiolabeled compounds from the TSLs in the blood by heating the blood in peripheral tissues can achieve rapid clearance of radioactivity, resulting in improved imaging contrast. To demonstrate the hypothesis, classical TSLs mainly composed of 1,2-dipalmitoyl-sn-glycero-3-phosphocholine with a phase transition temperature of 41 °C were used. The optimal composition of TSLs was determined by an in vitro release test using [111In]In-diethylenetriaminepentaacetic acid (DTPA)-encapsulated liposomes, which showed that the cholesterol content drastically changed the release characteristics of classical TSLs. In the biodistribution experiments, [111In]In-DTPA was significantly released from the TSLs in the blood when the tails of mice were heated at 43 °C. The tumor-to-blood ratio of the heated group was three times higher than that of the nonheated group, and accumulation in normal tissues of the heated group was lower than that of the nonheated group. These results demonstrate the usefulness of the method using TSLs to encapsulate urinary excretable radiolabeled compounds for improving imaging contrast.
Collapse
Affiliation(s)
- Masayuki Munekane
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
- Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan
| | - Miki Ozaki
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| | - Yuri Mitani
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| | - Natsuki Sakaida
- Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan
| | - Kohei Sano
- Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan
| | - Toshihide Yamasaki
- Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan
| | - Takahiro Mukai
- Laboratory of Biophysical Chemistry, Kobe Pharmaceutical University, 4-19-1 Motoyamakita-machi, Higashinada-ku, Kobe 658-8558, Japan
| | - Kenji Mishiro
- Institute for Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan
| | - Takeshi Fuchigami
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
| | - Kazuma Ogawa
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
- Institute for Frontier Science Initiative, Kanazawa University, Kanazawa 920-1192, Japan
| |
Collapse
|
5
|
Yin C, Hu P, Qin L, Wang Z, Zhao H. The Current Status and Future Directions on Nanoparticles for Tumor Molecular Imaging. Int J Nanomedicine 2024; 19:9549-9574. [PMID: 39296941 PMCID: PMC11409933 DOI: 10.2147/ijn.s484206] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/25/2024] [Accepted: 08/29/2024] [Indexed: 09/21/2024] Open
Abstract
Molecular imaging is an advanced technology that utilizes specific probes or markers in conjunction with cutting-edge imaging techniques to observe and analyze the localization, distribution, activity, and interactions of biomolecules within living organisms. Tumor molecular imaging, by enabling the visualization and quantification of molecular characteristics of tumor cells, facilitates a deeper and more comprehensive understanding of tumors, providing valuable insights for early diagnosis, treatment monitoring, and cancer biology research. However, the image quality of molecular imaging still requires improvement, and nanotechnology has significantly propelled the advancement of molecular imaging. Currently, nanoparticle-based tumor molecular imaging technologies encompass radionuclide imaging, fluorescence imaging, magnetic resonance imaging, ultrasound imaging, photoacoustic imaging, and multimodal imaging, among others. As our understanding of the tumor microenvironment deepens, the design of nanoparticle probes for tumor molecular imaging has also evolved, offering new perspectives and expanding the applications of tumor molecular imaging. Beyond diagnostics, there is a marked trend towards integrated diagnosis and therapy, with image-guided treatment playing a pivotal role. This includes image-guided surgery, photodynamic therapy, and chemodynamic therapy. Despite continuous advancements and innovative developments in molecular imaging, many of these remain in the experimental stage and require breakthroughs before they can be fully integrated into clinical practice.
Collapse
Affiliation(s)
- Caiyun Yin
- Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, People's Republic of China
- National Health Commission (NHC) Key laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, People's Republic of China
| | - Peiyun Hu
- Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, People's Republic of China
- National Health Commission (NHC) Key laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, People's Republic of China
| | - Lijing Qin
- National Health Commission (NHC) Key laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, People's Republic of China
| | - Zhicheng Wang
- National Health Commission (NHC) Key laboratory of Radiobiology, School of Public Health, Jilin University, Changchun, People's Republic of China
| | - Hongguang Zhao
- Department of Nuclear Medicine, The First Hospital of Jilin University, Changchun, People's Republic of China
| |
Collapse
|
6
|
Azarkin M, Kirakosyan M, Ryabov V. Microdosimetric Simulation of Gold-Nanoparticle-Enhanced Radiotherapy. Int J Mol Sci 2024; 25:9525. [PMID: 39273472 PMCID: PMC11395083 DOI: 10.3390/ijms25179525] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/16/2024] [Revised: 08/20/2024] [Accepted: 08/29/2024] [Indexed: 09/15/2024] Open
Abstract
Conventional X-ray therapy (XRT) is commonly applied to suppress cancerous tumors; however, it often inflicts collateral damage to nearby healthy tissue. In order to provide a better conformity of the dose distribution in the irradiated tumor, proton therapy (PT) is increasingly being used to treat solid tumors. Furthermore, radiosensitization with gold nanoparticles (GNPs) has been extensively studied to increase the therapeutic ratio. The mechanism of radiosensitization is assumed to be connected to an enhancement of the absorbed dose due to huge photoelectric cross-sections with gold. Nevertheless, numerous theoretical studies, mostly based on Monte Carlo (MC) simulations, did not provide a consistent and thorough picture of dose enhancement and, therefore, the radiosensitization effect. Radiosensitization by nanoparticles in PT is even less studied than in XRT. Therefore, we investigate the physics picture of GNP-enhanced RT using an MC simulation with Geant4 equipped with the most recent physics models, taking into account a wide range of physics processes relevant for realistic PT and XRT. Namely, we measured dose enhancement factors in the vicinity of GNP, with diameters ranging from 10 nm to 80 nm. The dose enhancement in the vicinity of GNP reaches high values for XRT, while it is very modest for PT. The macroscopic dose enhancement factors for realistic therapeutic GNP concentrations are rather low for all RT scenarios; therefore, other physico-chemical and biological mechanisms should be additionally invoked for an explanation of the radiosensitization effect observed in many experiments.
Collapse
Affiliation(s)
- Maxim Azarkin
- P.N. Lebedev Physical Institute, 119991 Moscow, Russia
| | | | | |
Collapse
|
7
|
Jiao X, Hong H, Cai W. Nanoscale Radiotheranostics for Cancer Treatment: From Bench to Bedside. WILEY INTERDISCIPLINARY REVIEWS. NANOMEDICINE AND NANOBIOTECHNOLOGY 2024; 16:e2006. [PMID: 39407431 PMCID: PMC11486289 DOI: 10.1002/wnan.2006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/31/2024] [Revised: 08/31/2024] [Accepted: 09/23/2024] [Indexed: 10/19/2024]
Abstract
In recent years, the application of radionuclides-containing nanomaterials in cancer treatment has garnered widespread attention. The diversity of nanomaterials allows researchers to selectively combine them with appropriate radionuclides for biomedical purposes, addressing challenges faced by peptides, small molecules, or antibodies used for radionuclide labeling. However, with advantages come challenges, and nanoradionuclides still encounter significant issues during clinical translation. This review summarized the recent progress of nanosized radionuclides for cancer treatment or diagnosis. The discussion began with representative radionuclides and the methods of incorporating them into nanomaterial structures. Subsequently, new combinations of nanomaterials and radionuclides, along with their applications, were introduced to demonstrate their future trends. The benefits of nanoradionuclides included optimized pharmacokinetic properties, enhanced disease-targeting efficacy, and synergistic application with other treatment techniques. Besides, the basic rule of this section was to summarize how these nanoradionuclides can truly impact the diagnosis and therapy of various cancer types. In the last part, the focus was devoted to the nanoradionuclides currently applicable in clinics and how to address the existing issues and problems based on our knowledge.
Collapse
Affiliation(s)
- Xiaodan Jiao
- State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing 210093, China
| | - Hao Hong
- State Key Laboratory of Pharmaceutical Biotechnology, Chemistry and Biomedicine Innovation Center (ChemBIC), Jiangsu Key Laboratory of Molecular Medicine, Medical School of Nanjing University, 22 Hankou Road, Nanjing 210093, China
| | - Weibo Cai
- Departments of Radiology and Medical Physics, University of Wisconsin-Madison, 1111 Highland Avenue, Madison, WI, USA
| |
Collapse
|
8
|
Andrew J, Ezra-Manicum AL, Witika BA. Developments in radionanotheranostic strategies for precision diagnosis and treatment of prostate cancer. EJNMMI Radiopharm Chem 2024; 9:62. [PMID: 39180599 PMCID: PMC11344754 DOI: 10.1186/s41181-024-00295-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/13/2024] [Accepted: 08/13/2024] [Indexed: 08/26/2024] Open
Abstract
BACKGROUND Prostate Cancer (PCa) is the second most diagnosed urological cancer among men worldwide. Conventional methods used for diagnosis of PCa have several pitfalls which include lack of sensitivity and specificity. On the other hand, traditional treatment of PCa poses challenges such as long-term side effects and the development of multidrug resistance (MDR). MAIN BODY Hence, there is a need for novel PCa agents with the potential to lessen the burden of these adverse effects on patients. Nanotechnology has emerged as a promising approach to support both early diagnosis and effective treatment of tumours by ensuring precise delivery of the drug to the targeted site of the disease. Most cancer-related biological processes occur on the nanoscale hence application of nanotechnology has been greatly appreciated and implemented in the management and therapeutics of cancer. Nuclear medicine plays a significant role in the non-invasive diagnosis and treatment of PCa using appropriate radiopharmaceuticals. This review aims to explore the different radiolabelled nanomaterials to enhance the specific delivery of imaging and therapeutic agents to cancer cells. Thereafter, the review appraises the advantages and disadvantages of these modalities and then discusses and outlines the benefits of radiolabelled nanomaterials in targeting cancerous prostatic tumours. Moreover, the nanoradiotheranostic approaches currently developed for PCa are discussed and finally the prospects of combining radiopharmaceuticals with nanotechnology in improving PCa outcomes will be highlighted. CONCLUSION Nanomaterials have great potential, but safety and biocompatibility issues remain. Notwithstanding, the combination of nanomaterials with radiotherapeutics may improve patient outcomes and quality of life.
Collapse
Affiliation(s)
- Jubilee Andrew
- Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, 0208, South Africa
| | - Amanda-Lee Ezra-Manicum
- Department of Chemistry, Faculty of Science, Tshwane University of Technology (Arcadia Campus), Pretoria, South Africa
| | - Bwalya Angel Witika
- Department of Pharmaceutical Sciences, School of Pharmacy, Sefako Makgatho Health Sciences University, Pretoria, 0208, South Africa.
| |
Collapse
|
9
|
Popov AL, Kolmanovich DD, Chukavin NN, Zelepukin IV, Tikhonowski GV, Pastukhov AI, Popov AA, Shemyakov AE, Klimentov SM, Ryabov VA, Deyev SM, Zavestovskaya IN, Kabashin AV. Boron Nanoparticle-Enhanced Proton Therapy: Molecular Mechanisms of Tumor Cell Sensitization. Molecules 2024; 29:3936. [PMID: 39203014 PMCID: PMC11357428 DOI: 10.3390/molecules29163936] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/19/2024] [Revised: 08/15/2024] [Accepted: 08/16/2024] [Indexed: 09/03/2024] Open
Abstract
Boron-enhanced proton therapy has recently appeared as a promising approach to increase the efficiency of proton therapy on tumor cells, and this modality can further be improved by the use of boron nanoparticles (B NPs) as local sensitizers to achieve enhanced and targeted therapeutic outcomes. However, the mechanisms of tumor cell elimination under boron-enhanced proton therapy still require clarification. Here, we explore possible molecular mechanisms responsible for the enhancement of therapeutic outcomes under boron NP-enhanced proton therapy. Spherical B NPs with a mode size of 25 nm were prepared by methods of pulsed laser ablation in water, followed by their coating by polyethylene glycol to improve their colloidal stability in buffers. Then, we assessed the efficiency of B NPs as sensitizers of cancer cell killing under irradiation with a 160.5 MeV proton beam. Our experiments showed that the combined effect of B NPs and proton irradiation induces an increased level of superoxide anion radical generation, which leads to the depolarization of mitochondria, a drop in their membrane mitochondrial potential, and the development of apoptosis. A comprehensive gene expression analysis (via RT-PCR) confirmed increased overexpression of 52 genes (out of 87 studied) involved in the cell redox status and oxidative stress, compared to 12 genes in the cells irradiated without B NPs. Other possible mechanisms responsible for the B NPs-induced radiosensitizing effect, including one related to the generation of alpha particles, are discussed. The obtained results give a better insight into the processes involved in the boron-induced enhancement of proton therapy and enable one to optimize parameters of proton therapy in order to maximize therapeutic outcomes.
Collapse
Affiliation(s)
- Anton L. Popov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, Moscow 119991, Russia; (A.L.P.); (D.D.K.); (A.E.S.); (V.A.R.)
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 3 Institutskaya St., Pushchino 142290, Russia;
| | - Danil D. Kolmanovich
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, Moscow 119991, Russia; (A.L.P.); (D.D.K.); (A.E.S.); (V.A.R.)
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 3 Institutskaya St., Pushchino 142290, Russia;
| | - Nikita N. Chukavin
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 3 Institutskaya St., Pushchino 142290, Russia;
| | - Ivan V. Zelepukin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia; (I.V.Z.); (S.M.D.)
- Department of Medicinal Chemistry, Uppsala University, 75310 Uppsala, Sweden
| | - Gleb V. Tikhonowski
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Kashirskoe Shosse 31, Moscow 115409, Russia; (G.V.T.); (A.A.P.); (S.M.K.)
| | | | - Anton A. Popov
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Kashirskoe Shosse 31, Moscow 115409, Russia; (G.V.T.); (A.A.P.); (S.M.K.)
| | - Alexander E. Shemyakov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, Moscow 119991, Russia; (A.L.P.); (D.D.K.); (A.E.S.); (V.A.R.)
| | - Sergey M. Klimentov
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Kashirskoe Shosse 31, Moscow 115409, Russia; (G.V.T.); (A.A.P.); (S.M.K.)
| | - Vladimir A. Ryabov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, Moscow 119991, Russia; (A.L.P.); (D.D.K.); (A.E.S.); (V.A.R.)
| | - Sergey M. Deyev
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow 117997, Russia; (I.V.Z.); (S.M.D.)
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Kashirskoe Shosse 31, Moscow 115409, Russia; (G.V.T.); (A.A.P.); (S.M.K.)
- National Research Center “Kurchatov Institute”, Academician Kurchatov Square 1, Moscow 123182, Russia
- “Biomarker” Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, 18 Kremlyovskaya St., Kazan 420008, Russia
- Institute of Molecular Theranostics, Sechenov University, Moscow 119991, Russia
| | - Irina N. Zavestovskaya
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, Moscow 119991, Russia; (A.L.P.); (D.D.K.); (A.E.S.); (V.A.R.)
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Kashirskoe Shosse 31, Moscow 115409, Russia; (G.V.T.); (A.A.P.); (S.M.K.)
- National Research Center “Kurchatov Institute”, Academician Kurchatov Square 1, Moscow 123182, Russia
| | | |
Collapse
|
10
|
Xi Z, Yao H, Zhang T, Su Z, Wang B, Feng W, Pu Q, Zhao L. Quantitative Three-Dimensional Imaging Analysis of HfO 2 Nanoparticles in Single Cells via Deep Learning Aided X-ray Nano-Computed Tomography. ACS NANO 2024; 18:22378-22389. [PMID: 39115329 PMCID: PMC11342356 DOI: 10.1021/acsnano.4c06953] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2024] [Revised: 07/29/2024] [Accepted: 07/31/2024] [Indexed: 08/21/2024]
Abstract
It is crucial for understanding mechanisms of drug action to quantify the three-dimensional (3D) drug distribution within a single cell at nanoscale resolution. Yet it remains a great challenge due to limited lateral resolution, detection sensitivities, and reconstruction problems. The preferable method is using X-ray nano-computed tomography (Nano-CT) to observe and analyze drug distribution within cells, but it is time-consuming, requiring specialized expertise, and often subjective, particularly with ultrasmall metal nanoparticles (NPs). Furthermore, the accuracy of batch data analysis through conventional processing methods remains uncertain. In this study, we used radioenhancer ultrasmall HfO2 nanoparticles as a model to develop a modular and automated deep learning aided Nano-CT method for the localization quantitative analysis of ultrasmall metal NPs uptake in cancer cells. We have established an ultrasmall objects segmentation method for 3D Nano-CT images in single cells, which can highly sensitively analyze minute NPs and even ultrasmall NPs in single cells. We also constructed a localization quantitative analysis method, which may accurately segment the intracellularly bioavailable particles from those of the extracellular space and intracellular components and NPs. The high bioavailability of HfO2 NPs in tumor cells from deeper penetration in tumor tissue and higher tumor intracellular uptake provide mechanistic insight into HfO2 NPs as advanced radioenhancers in the combination of quantitative subcellular image analysis with the therapeutic effects of NPs on 3D tumor spheroids and breast cancer. Our findings unveil the substantial uptake rate and subcellular quantification of HfO2 NPs by the human breast cancer cell line (MCF-7). This revelation explicates the notable efficacy and safety profile of HfO2 NPs in tumor treatment. These findings demonstrate that this 3D imaging technique promoted by the deep learning algorithm has the potential to provide localization quantitative information about the 3D distributions of specific molecules at the nanoscale level. This study provides an approach for exploring the subcellular quantitative analysis of NPs in single cells, offering a valuable quantitative imaging tool for minute amounts or ultrasmall NPs.
Collapse
Affiliation(s)
- Zuoxin Xi
- Multi-disciplinary
Research Division, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- School
of Information Engineering, Minzu University
of China, Beijing 100081, China
| | - Haodong Yao
- Multi-disciplinary
Research Division, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University
of Chinese Academy of Sciences, Beijing 100049, China
| | - Tingfeng Zhang
- Multi-disciplinary
Research Division, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University
of Chinese Academy of Sciences, Beijing 100049, China
| | - Zongyi Su
- Multi-disciplinary
Research Division, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
| | - Bing Wang
- Multi-disciplinary
Research Division, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University
of Chinese Academy of Sciences, Beijing 100049, China
| | - Weiyue Feng
- Multi-disciplinary
Research Division, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University
of Chinese Academy of Sciences, Beijing 100049, China
| | - Qiumei Pu
- School
of Information Engineering, Minzu University
of China, Beijing 100081, China
| | - Lina Zhao
- Multi-disciplinary
Research Division, Institute of High Energy Physics, Chinese Academy of Sciences, Beijing 100049, China
- University
of Chinese Academy of Sciences, Beijing 100049, China
| |
Collapse
|
11
|
Li H, Guan M, Zhang NN, Wang Y, Liang T, Wu H, Wang C, Sun T, Liu S. Harnessing nanomedicine for modulating microglial states in the central nervous system disorders: Challenges and opportunities. Biomed Pharmacother 2024; 177:117011. [PMID: 38917758 DOI: 10.1016/j.biopha.2024.117011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2024] [Revised: 05/30/2024] [Accepted: 06/17/2024] [Indexed: 06/27/2024] Open
Abstract
Microglia are essential for maintaining homeostasis and responding to pathological events in the central nervous system (CNS). Their dynamic and multidimensional states in different environments are pivotal factors in various CNS disorders. However, therapeutic modulation of microglial states is challenging due to the intricate balance these cells maintain in the CNS environment and the blood-brain barrier's restriction of drug delivery. Nanomedicine presents a promising avenue for addressing these challenges, offering a method for the targeted and efficient modulation of microglial states. This review covers the challenges faced in microglial therapeutic modulation and potential use of nanoparticle-based drug delivery systems. We provide an in-depth examination of nanoparticle applications for modulating microglial states in a range of CNS disorders, encompassing neurodegenerative and autoimmune diseases, infections, traumatic injuries, stroke, tumors, chronic pain, and psychiatric conditions. This review highlights the recent advancements and future prospects in nanomedicine for microglial modulation, paving the way for future research and clinical applications of therapeutic interventions in CNS disorders.
Collapse
Affiliation(s)
- Haisong Li
- Cancer Center, The First Hospital, Jilin University, Changchun, Jilin, China; Department of Neurosurgery, The First Hospital, Jilin University, Changchun, Jilin, China
| | - Meng Guan
- Cancer Center, The First Hospital, Jilin University, Changchun, Jilin, China; Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China; National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin, China
| | - Ning-Ning Zhang
- State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, Jilin, China
| | - Yizhuo Wang
- Cancer Center, The First Hospital, Jilin University, Changchun, Jilin, China
| | - Tingting Liang
- Cancer Center, The First Hospital, Jilin University, Changchun, Jilin, China
| | - Haitao Wu
- Cancer Center, The First Hospital, Jilin University, Changchun, Jilin, China
| | - Chang Wang
- Cancer Center, The First Hospital, Jilin University, Changchun, Jilin, China.
| | - Tianmeng Sun
- Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China; National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin, China; International Center of Future Science, Jilin University, Changchun, Jilin, China; State Key Laboratory of Supramolecular Structure and Materials, Jilin University, Changchun, Jilin, China.
| | - Shuhan Liu
- Cancer Center, The First Hospital, Jilin University, Changchun, Jilin, China; Key Laboratory of Organ Regeneration and Transplantation of Ministry of Education, Institute of Immunology, The First Hospital, Jilin University, Changchun, Jilin, China; National-local Joint Engineering Laboratory of Animal Models for Human Diseases, Changchun, Jilin, China.
| |
Collapse
|
12
|
Trusova V, Karnaukhov I, Zelinsky A, Borts B, Ushakov I, Sidenko L, Gorbenko G. Radiolabeling of bionanomaterials with technetium 99m: current state and future prospects. Nanomedicine (Lond) 2024; 19:1569-1580. [PMID: 39011593 PMCID: PMC11321418 DOI: 10.1080/17435889.2024.2368454] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/04/2024] [Accepted: 06/12/2024] [Indexed: 07/17/2024] Open
Abstract
Radiolabeling of bionanomaterials with technetium-99m (99mTc) has become a promising approach in combining the benefits of nanotechnology and nuclear medicine for diagnostic and therapeutic purposes. This review is intended to provide a comprehensive overview of the state-of-the-art of radiolabeling of bionanomaterials with 99mTc, highlighting the synthesis methods, labeling mechanisms, biological evaluation, physicochemical characterization and clinical applications of 99mTc-labeled bionanomaterials. Various types of nanomaterials are considered in the review, including lipid- and protein-based nanosystems, dendrimers and polymeric nanomaterials. Moreover, the review assesses the challenges presented by this emerging field, such as stability of the radiolabel, potential toxicity of the nanomaterials and regulatory aspects. Finally, promising future perspectives and areas of research development in 99mTc-labeled bionanomaterials are discussed.
Collapse
Affiliation(s)
- Valeriya Trusova
- Department of Medical Physics & Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv61022, Ukraine
| | - Ivan Karnaukhov
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Andrey Zelinsky
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Borys Borts
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Igor Ushakov
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Larysa Sidenko
- National Science Center “Kharkov Institute of Physics and Technology”, Kharkiv, Ukraine
| | - Galyna Gorbenko
- Department of Medical Physics & Biomedical Nanotechnologies, V.N. Karazin Kharkiv National University, 4 Svobody Sq., Kharkiv61022, Ukraine
| |
Collapse
|
13
|
Munekane M, Fuchigami T, Ogawa K. Recent advances in the development of 225Ac- and 211At-labeled radioligands for radiotheranostics. ANAL SCI 2024; 40:803-826. [PMID: 38564087 PMCID: PMC11035452 DOI: 10.1007/s44211-024-00514-w] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2023] [Accepted: 01/16/2024] [Indexed: 04/04/2024]
Abstract
Radiotheranostics utilizes a set of radioligands incorporating diagnostic or therapeutic radionuclides to achieve both diagnosis and therapy. Imaging probes using diagnostic radionuclides have been used for systemic cancer imaging. Integration of therapeutic radionuclides into the imaging probes serves as potent agents for radionuclide therapy. Among them, targeted alpha therapy (TAT) is a promising next-generation cancer therapy. The α-particles emitted by the radioligands used in TAT result in a high linear energy transfer over a short range, inducing substantial damage to nearby cells surrounding the binding site. Therefore, the key to successful cancer treatment with minimal side effects by TAT depends on the selective delivery of radioligands to their targets. Recently, TAT agents targeting biomolecules highly expressed in various cancer cells, such as sodium/iodide symporter, norepinephrine transporter, somatostatin receptor, αvβ3 integrin, prostate-specific membrane antigen, fibroblast-activation protein, and human epidermal growth factor receptor 2 have been developed and have made remarkable progress toward clinical application. In this review, we focus on two radionuclides, 225Ac and 211At, which are expected to have a wide range of applications in TAT. We also introduce recent fundamental and clinical studies of radiopharmaceuticals labeled with these radionuclides.
Collapse
Affiliation(s)
- Masayuki Munekane
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan
| | - Takeshi Fuchigami
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan.
| | - Kazuma Ogawa
- Graduate School of Medical Sciences, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan.
- Institute for Frontier Science Initiative, Kanazawa University, Kakuma-Machi, Kanazawa, Ishikawa, 920-1192, Japan.
| |
Collapse
|
14
|
Zhao LX, Chen LL, Cheng D, Wu TY, Fan YG, Wang ZY. Potential Application Prospects of Biomolecule-Modified Two-Dimensional Chiral Nanomaterials in Biomedicine. ACS Biomater Sci Eng 2024; 10:2022-2040. [PMID: 38506625 DOI: 10.1021/acsbiomaterials.3c01871] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/21/2024]
Abstract
Chirality, one of the most fundamental properties of natural molecules, plays a significant role in biochemical reactions. Nanomaterials with chiral characteristics have superior properties, such as catalytic properties, optoelectronic properties, and photothermal properties, which have significant potential for specific applications in nanomedicine. Biomolecular modifications such as nucleic acids, peptides, proteins, and polysaccharides are sources of chirality for nanomaterials with great potential for application in addition to intrinsic chirality, artificial macromolecules, and metals. Two-dimensional (2D) nanomaterials, as opposed to other dimensions, due to proper surface area, extensive modification sites, drug loading potential, and simplicity of preparation, are prepared and utilized in diagnostic applications, drug delivery research, and tumor therapy. Current advanced studies on 2D chiral nanomaterials for biomedicine are focused on novel chiral development, structural control, and materials sustainability applications. However, despite the advances in biomedical research, chiral 2D nanomaterials still confront challenges such as the difficulty of synthesis, quality control, batch preparation, chiral stability, and chiral recognition and selectivity. This review aims to provide a comprehensive overview of the origins, synthesis, applications, and challenges of 2D chiral nanomaterials with biomolecules as cargo and chiral modifications and highlight their potential roles in biomedicine.
Collapse
Affiliation(s)
- Ling-Xiao Zhao
- Key Laboratory of Medical Cell Biology of Ministry of Education, Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province, Health Sciences Institute of China Medical University, Shenyang 110122, China
| | - Li-Lin Chen
- Key Laboratory of Medical Cell Biology of Ministry of Education, Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province, Health Sciences Institute of China Medical University, Shenyang 110122, China
| | - Di Cheng
- Dalian Gentalker Biological Technology Co., Ltd., Dalian 116699, China
| | - Ting-Yao Wu
- First Affiliated Hospital of Jinzhou Medical University, Jinzhou 121000, China
| | - Yong-Gang Fan
- Key Laboratory of Medical Cell Biology of Ministry of Education, Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province, Health Sciences Institute of China Medical University, Shenyang 110122, China
| | - Zhan-You Wang
- Key Laboratory of Medical Cell Biology of Ministry of Education, Key Laboratory of Major Chronic Diseases of Nervous System of Liaoning Province, Health Sciences Institute of China Medical University, Shenyang 110122, China
| |
Collapse
|
15
|
Filimonova MV, Soldatova OV, Shitova AA, Filimonov AS, Rybachuk VA, Kosachenko AO, Nikolaev KA, Demyashkin GA, Popov AA, Zelepukin IV, Kabashin AV, Deev SM, Kaprin AD, Shegay PV, Ivanov SA, Zavestovskaya IN, Koryakin SN. Bismuth Nanoparticles Increase Effectiveness of Proton Therapy of Ehrlich Carcinoma. Bull Exp Biol Med 2024; 176:626-630. [PMID: 38730109 DOI: 10.1007/s10517-024-06081-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2023] [Indexed: 05/12/2024]
Abstract
We studied the antitumor activity of the combined use of local proton irradiation in two modes (10 and 31 Gy) with preliminary intra-tumoral injection of two types of bismuth nanoparticles differing in surface coating: coated with the amphiphilic molecule Pluronic-F127 or Silane-PEG (5 kDa)-COOH polymer. Nanoparticles were used in doses of 0.75 and 1.5 mg/mouse. In two independent series on experimental tumor model (solid Ehrlich carcinoma), bismuth nanoparticles of both modifications injected directly into the tumor enhanced the antitumor effects of proton therapy. Moreover, the radiosensitizing effect of bismuth nanoparticles administered via this route increased with the increasing the doses of nanoparticles and the doses of radiation exposure. In our opinion, these promising data obtained for the first time extend the possibilities of treating malignant neoplasms.
Collapse
Affiliation(s)
- M V Filimonova
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia.
- Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI, Obninsk, Russia.
| | - O V Soldatova
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
| | - A A Shitova
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
| | - A S Filimonov
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
| | - V A Rybachuk
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
| | - A O Kosachenko
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
| | - K A Nikolaev
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
| | - G A Demyashkin
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
| | - A A Popov
- National Research Nuclear University MEPhI, Moscow, Russia
| | - I V Zelepukin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | | | - S M Deev
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, Moscow, Russia
| | - A D Kaprin
- National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russia
- Patrice Lumumba Peoples' Friendship University of Russia, (RUDN University), Moscow, Russia
| | - P V Shegay
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
- National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Moscow, Russia
| | - S A Ivanov
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
- Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI, Obninsk, Russia
- Patrice Lumumba Peoples' Friendship University of Russia, (RUDN University), Moscow, Russia
| | - I N Zavestovskaya
- P. N. Lebedev Physical Institute, Russian Academy of Sciences, Moscow, Russia
| | - S N Koryakin
- A. Tsyb Medical Radiological Research Center - Branch of the National Medical Research Radiological Centre, Ministry of Health of the Russian Federation, Obninsk, Russia
- Obninsk Institute for Nuclear Power Engineering, National Research Nuclear University MEPhI, Obninsk, Russia
| |
Collapse
|
16
|
Fu Y, Zhang H, Ye J, Chen C, Yang Y, Wu B, Yin X, Shi J, Zhu Y, Zhao C, Zhang W. An "all-in-one" treatment and imaging nanoplatform for breast cancer with photothermal nanoparticles. NANOSCALE ADVANCES 2024; 6:1423-1435. [PMID: 38419880 PMCID: PMC10898424 DOI: 10.1039/d3na00814b] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Accepted: 01/22/2024] [Indexed: 03/02/2024]
Abstract
Drug delivery systems based on nanoparticles still face challenges of low efficacy and an inability to track treatment effects in tumor therapy due to biological barriers. This limitation hinders clinicians' ability to determine treatment effects and proper drug dosages, thus, ultimately impeding the further application and transformation of nanoplatforms. To address this challenge, an all-in-one nanoplatform for therapy and imaging is proposed. The nanoplatform is constructed by using nanoparticles through the co-encapsulation of the photothermal therapeutic agent IR780, the passively targeted drug OA@Fe3O4, and the chemotherapeutic drug paclitaxel. Under the guidance of magnetic navigation, the nanoparticles can enhance local enrichment of the drug, while the luminescence properties of IR780 enable drug tracking at the same time. Remarkably, the nanoparticles exhibit improved photothermal-chemotherapy synergy under magnetic targeting guidance, demonstrating antitumor effects in both in vitro and in vivo experiments. It is demonstrated that the use of these polymeric nanoparticles has significant potential for future biomedical applications and clinical decisions.
Collapse
Affiliation(s)
- Yuping Fu
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210008 China
| | - Hongmei Zhang
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210008 China
| | - Jiahui Ye
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Changrong Chen
- Division of Emergency Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Yaxuan Yang
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Baojuan Wu
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Xi Yin
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Jiajun Shi
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Yun Zhu
- Division of Pharmacy Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Cheng Zhao
- Department of Gastroenterology, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| | - Weijie Zhang
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, Nanjing Drum Tower Hospital Clinical College of Traditional Chinese and Western Medicine, Nanjing University of Chinese Medicine Nanjing 210008 China
- Division of Breast Surgery, Department of General Surgery, Nanjing Drum Tower Hospital, The Affiliated Hospital of Medical School, Nanjing University Nanjing 210008 China
| |
Collapse
|
17
|
Xuan L, Bai C, Ju Z, Luo J, Guan H, Zhou PK, Huang R. Radiation-targeted immunotherapy: A new perspective in cancer radiotherapy. Cytokine Growth Factor Rev 2024; 75:1-11. [PMID: 38061920 DOI: 10.1016/j.cytogfr.2023.11.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2023] [Revised: 11/22/2023] [Accepted: 11/28/2023] [Indexed: 02/16/2024]
Abstract
In contemporary oncology, radiation therapy and immunotherapy stand as critical treatments, each with distinct mechanisms and outcomes. Radiation therapy, a key player in cancer management, targets cancer cells by damaging their DNA with ionizing radiation. Its effectiveness is heightened when used alongside other treatments like surgery and chemotherapy. Employing varied radiation types like X-rays, gamma rays, and proton beams, this approach aims to minimize damage to healthy tissue. However, it is not without risks, including potential damage to surrounding normal cells and side effects ranging from skin inflammation to serious long-term complications. Conversely, immunotherapy marks a revolutionary step in cancer treatment, leveraging the body's immune system to target and destroy cancer cells. It manipulates the immune system's specificity and memory, offering a versatile approach either alone or in combination with other treatments. Immunotherapy is known for its targeted action, long-lasting responses, and fewer side effects compared to traditional therapies. The interaction between radiation therapy and immunotherapy is intricate, with potential for both synergistic and antagonistic effects. Their combined use can be more effective than either treatment alone, but careful consideration of timing and sequence is essential. This review explores the impact of various radiation therapy regimens on immunotherapy, focusing on changes in the immune microenvironment, immune protein expression, and epigenetic factors, emphasizing the need for personalized treatment strategies and ongoing research to enhance the efficacy of these combined therapies in cancer care.
Collapse
Affiliation(s)
- Lihui Xuan
- Department of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan Province 410078, China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China
| | - Chenjun Bai
- Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China
| | - Zhao Ju
- Department of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan Province 410078, China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China
| | - Jinhua Luo
- Department of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan Province 410078, China; Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China
| | - Hua Guan
- Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China.
| | - Ping-Kun Zhou
- Department of Radiation Biology, Beijing Key Laboratory for Radiobiology, Beijing Institute of Radiation Medicine, Beijing 100850, China.
| | - Ruixue Huang
- Department of Occupational and Environmental Health, Xiangya School of Public Health, Central South University, Changsha, Hunan Province 410078, China.
| |
Collapse
|
18
|
Jiang X, Jiang X, Wu D, Xie W, Liu X, Zheng J. A pH-Sensitive Nanoparticle as Reactive Oxygen Species Amplifier to Regulate Tumor Microenvironment and Potentiate Tumor Radiotherapy. Int J Nanomedicine 2024; 19:709-725. [PMID: 38283195 PMCID: PMC10812755 DOI: 10.2147/ijn.s436160] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/05/2023] [Accepted: 01/10/2024] [Indexed: 01/30/2024] Open
Abstract
Background Radiotherapy is a widely used clinical tool for tumor treatment but can cause systemic toxicity if excessive radiation is administered. Although numerous nanoparticles have been developed as radiosensitizers to reduce the required dose of X-ray irradiation, they often have limitations, such as passive reliance on radiation-induced apoptosis in tumors, and little consider the unique tumor microenvironment that contributes radiotherapy resistance. Methods In this study, we developed and characterized a novel self-assembled nanoparticle containing dysprosium ion and manganese ion (Dy/Mn-P). We systematically investigated the potential of Dy/Mn-P nanoparticles (NPs) as a reactive oxygen species (ROS) amplifier and radiosensitizer to enhance radiation therapy and modulate the tumor microenvironment at the cellular level. Additionally, we evaluated the effect of Dy/Mn-P on the stimulator of interferon genes (STING), an innate immune signaling pathway. Results Physicochemical analysis demonstrated the prepared Dy/Mn-P NPs exhibited excellent dispersibility and stability, and degraded rapidly at lower pH values. Furthermore, Dy/Mn-P was internalized by cells and exhibited selective toxicity towards tumor cells compared to normal cells. Our findings also revealed that Dy/Mn-P NPs improved the tumor microenvironment and significantly increased ROS generation under ionizing radiation, resulting in a ~70% increase in ROS levels compared to radiation therapy alone. This enhanced ROS generation inhibited ~92% of cell clone formation and greatly contributed to cytoplasmic DNA exposure. Subsequently, the activation of the STING pathway was observed, leading to the secretion of pro-inflammatory immune factors and maturation of dendritic cells (DCs). Conclusion Our study demonstrates that Dy/Mn-P NPs can potentiate tumor radiotherapy by improving the tumor microenvironment and increasing endogenous ROS levels within the tumor. Furthermore, Dy/Mn-P can amplify the activation of the STING pathway during radiotherapy, thereby triggering an anti-tumor immune response. This novel approach has the potential to expand the application of radiotherapy in tumor treatment.
Collapse
Affiliation(s)
- Xiaomei Jiang
- Department of Dermatology, Liuzhou Traditional Chinese Medicine Hospital, Liuzhou, 545001, People’s Republic of China
| | - Xiaohong Jiang
- Department of Pharmacy, Shantou University Medical College, Shantou, 515041, People’s Republic of China
| | - Dongjie Wu
- Department of Dermatology, Liuzhou Traditional Chinese Medicine Hospital, Liuzhou, 545001, People’s Republic of China
| | - Wanzhu Xie
- Department of Rehabilitation, Liuzhou Worker’s Hospital, Liuzhou, 545001, People’s Republic of China
| | - Xiong Liu
- Department of Dermatology, Liuzhou Traditional Chinese Medicine Hospital, Liuzhou, 545001, People’s Republic of China
| | - Jintao Zheng
- Department of Biotechnology and Food Engineering, Guangdong Technology Israel Institute of Technology, Shantou, 515063, People’s Republic of China
| |
Collapse
|
19
|
Xu H, Guo Z, Li M, Chaves HV, Pinto VDPT, Filho GC, Du M, Bezerra MM. Copper-Based Nanomaterials for Image-Guided Cancer Therapy. BIO INTEGRATION 2024; 5. [DOI: 10.15212/bioi-2024-0013] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2025] Open
Abstract
Abstract
Cancer is a significant disease that poses a major threat to human health. Image-guided cancer therapy refers to a series of medical procedures that use imaging technology to precisely locate and treat cancer. Combining the dual characteristics of medical images and functional nanomaterial (NM) drug carriers, various integrated diagnosis and treatment probes have been developed for in vivo dynamic monitoring and therapeutic effect evaluation of drugs based on medical imaging. Copper (Cu)-based NMs have emerged as valuable products of nanotechnology due to their unique physicochemical properties, which are influenced by factors, such as size, shape, and surface properties. In the field of imaging, Cu-based NMs offer a combination of desirable characteristics, including fluorescence emission, contrast enhancement, and radiolabeling stability. These properties form the foundation for a wide range of imaging modalities. In addition, Cu-based NMs can be used as a carrier for diagnostic or therapeutic drugs and the synergistic effect of multiple therapeutic modalities can be realized by doping multiple transition metals into the heterostructures. These properties have become an important basis for imaging-guided therapy with Cu-based NMs. In this review we introduce biocompatible Cu-based NMs for image-guided cancer therapy and provide an overview of the promising outcomes in biomedical research.
Collapse
|
20
|
Taheri-Ledari R, Ganjali F, Zarei-Shokat S, Dinmohammadi R, Asl FR, Emami A, Mojtabapour ZS, Rashvandi Z, Kashtiaray A, Jalali F, Maleki A. Plasmonic porous micro- and nano-materials based on Au/Ag nanostructures developed for photothermal cancer therapy: challenges in clinicalization. NANOSCALE ADVANCES 2023; 5:6768-6786. [PMID: 38059020 PMCID: PMC10696950 DOI: 10.1039/d3na00763d] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 09/10/2023] [Accepted: 11/13/2023] [Indexed: 12/08/2023]
Abstract
Photothermal therapy (PTT) has developed in recent decades as a relatively safe method for the treatment of cancers. Recently, various species of gold and silver (Au and Ag) nanostructures have been developed and investigated to achieve PTT due to their highly localized surface plasmon resonance (LSPR) effect. Concisely, the collective oscillation of electrons on the surface of Au and Ag nanostructures upon exposure to a specific wavelength (depending on their size and shape) and further plasmonic resonance leads to the heating of the surface of these particles. Hence, porous species can be equipped with tiny plasmonic ingredients that add plasmonic properties to therapeutic cargoes. In this case, a precise review of the recent achievements is very important to figure out to what extent plasmonic photothermal therapy (PPTT) by Au/Ag-based plasmonic porous nanomedicines successfully treated cancers with satisfactory biosafety. Herein, we classify the various species of LSPR-active micro- and nano-materials. Moreover, the routes for the preparation of Ag/Au-plasmonic porous cargoes and related bench assessments are carefully reviewed. Finally, as the main aim of this study, principal requirements for the clinicalization of Ag/Au-plasmonic porous cargoes and their further challenges are discussed, which are critical for specialists in this field.
Collapse
Affiliation(s)
- Reza Taheri-Ledari
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Fatemeh Ganjali
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Simindokht Zarei-Shokat
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Reihane Dinmohammadi
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Fereshteh Rasouli Asl
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Ali Emami
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Zahra Sadat Mojtabapour
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Zahra Rashvandi
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Amir Kashtiaray
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Farinaz Jalali
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| | - Ali Maleki
- Catalysts and Organic Synthesis Research Laboratory, Department of Chemistry, Iran University of Science and Technology Tehran 16846-13114 Iran +98 2173021584 +98 21 77240640-50
| |
Collapse
|
21
|
Zavestovskaya IN, Kasatova AI, Kasatov DA, Babkova JS, Zelepukin IV, Kuzmina KS, Tikhonowski GV, Pastukhov AI, Aiyyzhy KO, Barmina EV, Popov AA, Razumov IA, Zavjalov EL, Grigoryeva MS, Klimentov SM, Ryabov VA, Deyev SM, Taskaev SY, Kabashin AV. Laser-Synthesized Elemental Boron Nanoparticles for Efficient Boron Neutron Capture Therapy. Int J Mol Sci 2023; 24:17088. [PMID: 38069412 PMCID: PMC10707216 DOI: 10.3390/ijms242317088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/19/2023] [Revised: 11/23/2023] [Accepted: 11/27/2023] [Indexed: 12/18/2023] Open
Abstract
Boron neutron capture therapy (BNCT) is one of the most appealing radiotherapy modalities, whose localization can be further improved by the employment of boron-containing nanoformulations, but the fabrication of biologically friendly, water-dispersible nanoparticles (NPs) with high boron content and favorable physicochemical characteristics still presents a great challenge. Here, we explore the use of elemental boron (B) NPs (BNPs) fabricated using the methods of pulsed laser ablation in liquids as sensitizers of BNCT. Depending on the conditions of laser-ablative synthesis, the used NPs were amorphous (a-BNPs) or partially crystallized (pc-BNPs) with a mean size of 20 nm or 50 nm, respectively. Both types of BNPs were functionalized with polyethylene glycol polymer to improve colloidal stability and biocompatibility. The NPs did not initiate any toxicity effects up to concentrations of 500 µg/mL, based on the results of MTT and clonogenic assay tests. The cells with BNPs incubated at a 10B concentration of 40 µg/mL were then irradiated with a thermal neutron beam for 30 min. We found that the presence of BNPs led to a radical enhancement in cancer cell death, namely a drop in colony forming capacity of SW-620 cells down to 12.6% and 1.6% for a-BNPs and pc-BNPs, respectively, while the relevant colony-forming capacity for U87 cells dropped down to 17%. The effect of cell irradiation by neutron beam uniquely was negligible under these conditions. Finally, to estimate the dose and regimes of irradiation for future BNCT in vivo tests, we studied the biodistribution of boron under intratumoral administration of BNPs in immunodeficient SCID mice and recorded excellent retention of boron in tumors. The obtained data unambiguously evidenced the effect of a neutron therapy enhancement, which can be attributed to efficient BNP-mediated generation of α-particles.
Collapse
Affiliation(s)
- Irina N. Zavestovskaya
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (M.S.G.); (V.A.R.)
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Anna I. Kasatova
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Dmitry A. Kasatov
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Julia S. Babkova
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia
| | - Ivan V. Zelepukin
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia
| | - Ksenya S. Kuzmina
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Gleb V. Tikhonowski
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Andrei I. Pastukhov
- LP3, Aix-Marseille University, CNRS, 13288 Marseille, France; (A.I.P.); (A.V.K.)
| | - Kuder O. Aiyyzhy
- A. M. Prokhorov General Physics Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (K.O.A.); (E.V.B.)
| | - Ekaterina V. Barmina
- A. M. Prokhorov General Physics Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (K.O.A.); (E.V.B.)
| | - Anton A. Popov
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Ivan A. Razumov
- Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (I.A.R.); (E.L.Z.)
| | - Evgenii L. Zavjalov
- Institute of Cytology and Genetics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (I.A.R.); (E.L.Z.)
| | - Maria S. Grigoryeva
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (M.S.G.); (V.A.R.)
| | - Sergey M. Klimentov
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
| | - Vladimir A. Ryabov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Moscow 119991, Russia; (M.S.G.); (V.A.R.)
| | - Sergey M. Deyev
- Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI, Moscow 115409, Russia (I.V.Z.); (G.V.T.); (A.A.P.); (S.M.K.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, Moscow 117997, Russia
- Laboratory of Molecular Pharmacology, Institute of Molecular Theranostics, Sechenov First Moscow State Medical University (Sechenov University), Moscow 119991, Russia
- “Biomarker” Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, Kazan 420008, Russia
| | - Sergey Yu. Taskaev
- Laboratory of BNCT, Budker Institute of Nuclear Physics of the Siberian Branch of the Russian Academy of Sciences, Novosibirsk 630090, Russia; (A.I.K.); (D.A.K.); (K.S.K.); (S.Y.T.)
| | - Andrei V. Kabashin
- LP3, Aix-Marseille University, CNRS, 13288 Marseille, France; (A.I.P.); (A.V.K.)
| |
Collapse
|
22
|
Belyaev IB, Zelepukin IV, Tishchenko VK, Petriev VM, Trushina DB, Klimentov SM, Zavestovskaya IN, Ivanov SA, Kaprin AD, Deyev SM, Kabashin AV. Nanoparticles based on MIL-101 metal-organic frameworks as efficient carriers of therapeutic 188Re radionuclide for nuclear medicine. NANOTECHNOLOGY 2023; 35:075103. [PMID: 37963406 DOI: 10.1088/1361-6528/ad0c74] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/28/2023] [Accepted: 11/14/2023] [Indexed: 11/16/2023]
Abstract
Nuclear medicine presents one of the most promising modalities for efficient non-invasive treatment of a variety of cancers, but the application of radionuclides in cancer therapy and diagnostics is severely limited by their nonspecific tissue accumulation and poor biocompatibility. Here, we explore the use of nanosized metal-organic frameworks (MOFs) as carriers of radionuclides to order to improve their delivery to tumour. To demonstrate the concept, we prepared polymer-coated MIL-101(Cr)-NH2MOFs and conjugated them with clinically utilized radionuclide188Re. The nanoparticles demonstrated high loading efficacy of radionuclide reaching specific activity of 49 MBq mg-1. Pharmacokinetics of loaded MOFs was investigated in mice bearing colon adenocarcinoma. The biological half-life of the radionuclide in blood was (20.9 ± 1.3) h, and nanoparticles enabled it to passively accumulate and retain in the tumour. The radionuclide delivery with MOFs led to a significant decrease of radioactivity uptake by the thyroid gland and stomach as compared with perrhenate salt injection, which is beneficial for reducing the side toxicity of nuclear therapy. The reported data on the functionalization and pharmacokinetics of MIL-101(Cr)-NH2for radionuclide delivery unveils the promising potential of these MOFs for nuclear medicine.
Collapse
Affiliation(s)
- Iaroslav B Belyaev
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Institute for Physics and Engineering in Biomedicine (PhysBio), Moscow 115409, Russia
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia
| | - Ivan V Zelepukin
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Institute for Physics and Engineering in Biomedicine (PhysBio), Moscow 115409, Russia
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia
| | - Victoria K Tishchenko
- A. Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 249036 Obninsk, Russia
| | - Vasiliy M Petriev
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Institute for Physics and Engineering in Biomedicine (PhysBio), Moscow 115409, Russia
- A. Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 249036 Obninsk, Russia
| | - Daria B Trushina
- Federal Research Center 'Crystallography and Photonics', Russian Academy of Sciences, Moscow 119333, Russia
- Sechenov First Moscow State Medical University (Sechenov University), 119991, Moscow, Russia
| | - Sergey M Klimentov
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Institute for Physics and Engineering in Biomedicine (PhysBio), Moscow 115409, Russia
| | - Irina N Zavestovskaya
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Institute for Physics and Engineering in Biomedicine (PhysBio), Moscow 115409, Russia
| | - Sergey A Ivanov
- A. Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 249036 Obninsk, Russia
| | - Andrey D Kaprin
- A. Tsyb Medical Radiological Research Centre, Branch of the National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation, 249036 Obninsk, Russia
| | - Sergey M Deyev
- National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Institute for Physics and Engineering in Biomedicine (PhysBio), Moscow 115409, Russia
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 117997 Moscow, Russia
- Sechenov First Moscow State Medical University (Sechenov University), 119991, Moscow, Russia
- Kazan Federal University, Institute of Fundamental Medicine and Biology, 420008, Kazan, Russia
| | - Andrei V Kabashin
- Aix Marseille University, CNRS, LP3, Campus de Luminy, Case 917, F-13288, Marseille, France
| |
Collapse
|
23
|
Azarkin M, Kirakosyan M, Ryabov V. Study of Nuclear Reactions in Therapy of Tumors with Proton Beams. Int J Mol Sci 2023; 24:13400. [PMID: 37686211 PMCID: PMC10488192 DOI: 10.3390/ijms241713400] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/21/2023] [Revised: 08/17/2023] [Accepted: 08/25/2023] [Indexed: 09/10/2023] Open
Abstract
This paper presents an assessment of nuclear reaction yields of protons, α-particles, and neutrons in human tissue-equivalentmaterial in proton therapy using a simulation with Geant 4. In this study, we also check an enhancement of nuclear reactions due to the presence of Bi, Au, 11B, and 10B radiosensitizer nanoparticles. We demonstrate that a proton beam induces a noticeable amount of nuclear reactions in the tissue. Nevertheless, the enhancement of nuclear reaction products due to radiosensitizer nanoparticles is found to be negligible.
Collapse
Affiliation(s)
- Maxim Azarkin
- P. N. Lebedev Physical Institute, 119991 Moscow, Russia; (M.K.); (V.R.)
| | | | | |
Collapse
|
24
|
Al-Ibraheem A, Scott AM. 161Tb-PSMA Unleashed: a Promising New Player in the Theranostics of Prostate Cancer. Nucl Med Mol Imaging 2023; 57:168-171. [PMID: 37483873 PMCID: PMC10359225 DOI: 10.1007/s13139-023-00804-7] [Citation(s) in RCA: 9] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Revised: 04/12/2023] [Accepted: 04/13/2023] [Indexed: 07/25/2023] Open
Abstract
Radiotheranostics with 177Lu-PSMA have changed the treatment paradigm in patients with prostate cancer, becoming the new standard in certain settings. Terbium-161 (161Tb) has been recently investigated as a potential radionuclide for radiotheranostics in various types of cancer, including metastatic castration-resistant prostate cancer (mCRPC). The nuclear medicine team at King Hussein Cancer Center (KHCC) in Amman, Jordan, recently published the first-in-human SPECT/CT imaging results following a well-tolerated dose of 161Tb-PSMA radioligand therapy with no treatment-related adverse events, adding to the potential of radiotheranostics in prostate cancer. Two clinical trials for 161Tb-PSMA radioligand therapy in prostate cancer are currently underway and will provide valuable insights. This review will shed light on the expanding field of radiotheranostics in prostate cancer, which is not without challenges, and will discuss how the introduction of a new therapeutic option like 161Tb-PSMA may help to combat these challenges and build on the proven success of 177Lu-PSMA-based radiotheranostics for the benefit of prostate cancer patients worldwide.
Collapse
Affiliation(s)
- Akram Al-Ibraheem
- Department of Nuclear Medicine and PET/CT, King Hussein Cancer Center (KHCC), P.O. Box 1269, Al-Jubeiha, Amman, 11941 Jordan
- Department of Radiology and Nuclear Medicine, Division of Nuclear Medicine, University of Jordan, Amman, 11942 Jordan
| | - Andrew M. Scott
- Tumour Targeting Laboratory, Olivia Newton-John Cancer Research Institute, Melbourne, Victoria Australia
- Department of Molecular Imaging and Therapy, Austin Health, Melbourne, Victoria Australia
- School of Cancer Medicine, La Trobe University, Melbourne, Victoria Australia
- Department of Medicine, University of Melbourne, Melbourne, Victoria Australia
| |
Collapse
|
25
|
Zavestovskaya IN, Popov AL, Kolmanovich DD, Tikhonowski GV, Pastukhov AI, Savinov MS, Shakhov PV, Babkova JS, Popov AA, Zelepukin IV, Grigoryeva MS, Shemyakov AE, Klimentov SM, Ryabov VA, Prasad PN, Deyev SM, Kabashin AV. Boron Nanoparticle-Enhanced Proton Therapy for Cancer Treatment. NANOMATERIALS (BASEL, SWITZERLAND) 2023; 13:2167. [PMID: 37570485 PMCID: PMC10421420 DOI: 10.3390/nano13152167] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/16/2023] [Revised: 07/20/2023] [Accepted: 07/21/2023] [Indexed: 08/13/2023]
Abstract
Proton therapy is one of the promising radiotherapy modalities for the treatment of deep-seated and unresectable tumors, and its efficiency can further be enhanced by using boron-containing substances. Here, we explore the use of elemental boron (B) nanoparticles (NPs) as sensitizers for proton therapy enhancement. Prepared by methods of pulsed laser ablation in water, the used B NPs had a mean size of 50 nm, while a subsequent functionalization of the NPs by polyethylene glycol improved their colloidal stability in buffers. Laser-synthesized B NPs were efficiently absorbed by MNNG/Hos human osteosarcoma cells and did not demonstrate any remarkable toxicity effects up to concentrations of 100 ppm, as followed from the results of the MTT and clonogenic assay tests. Then, we assessed the efficiency of B NPs as sensitizers of cancer cell death under irradiation by a 160.5 MeV proton beam. The irradiation of MNNG/Hos cells at a dose of 3 Gy in the presence of 80 and 100 ppm of B NPs led to a 2- and 2.7-fold decrease in the number of formed cell colonies compared to control samples irradiated in the absence of NPs. The obtained data unambiguously evidenced the effect of a strong proton therapy enhancement mediated by B NPs. We also found that the proton beam irradiation of B NPs leads to the generation of reactive oxygen species (ROS), which evidences a possible involvement of the non-nuclear mechanism of cancer cell death related to oxidative stress. Offering a series of advantages, including a passive targeting option and the possibility of additional theranostic functionalities based on the intrinsic properties of B NPs (e.g., photothermal therapy or neutron boron capture therapy), the proposed concept promises a major advancement in proton beam-based cancer treatment.
Collapse
Affiliation(s)
- Irina N. Zavestovskaya
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, 119991 Moscow, Russia; (A.L.P.); (D.D.K.); (M.S.G.); (A.E.S.); (V.A.R.)
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
| | - Anton L. Popov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, 119991 Moscow, Russia; (A.L.P.); (D.D.K.); (M.S.G.); (A.E.S.); (V.A.R.)
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 3 Institutskaya St., 142290 Pushchino, Russia
| | - Danil D. Kolmanovich
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, 119991 Moscow, Russia; (A.L.P.); (D.D.K.); (M.S.G.); (A.E.S.); (V.A.R.)
- Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 3 Institutskaya St., 142290 Pushchino, Russia
| | - Gleb V. Tikhonowski
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
| | | | - Maxim S. Savinov
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
| | - Pavel V. Shakhov
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
| | - Julia S. Babkova
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia;
| | - Anton A. Popov
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
| | - Ivan V. Zelepukin
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia;
| | - Maria S. Grigoryeva
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, 119991 Moscow, Russia; (A.L.P.); (D.D.K.); (M.S.G.); (A.E.S.); (V.A.R.)
| | - Alexander E. Shemyakov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, 119991 Moscow, Russia; (A.L.P.); (D.D.K.); (M.S.G.); (A.E.S.); (V.A.R.)
| | - Sergey M. Klimentov
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
| | - Vladimir A. Ryabov
- P. N. Lebedev Physical Institute of the Russian Academy of Sciences, Leninsky Prospect 53, 119991 Moscow, Russia; (A.L.P.); (D.D.K.); (M.S.G.); (A.E.S.); (V.A.R.)
| | - Paras N. Prasad
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
- Department of Chemistry, Institute for Lasers, Photonics, and Biophotonics, The State University of New York at Buffalo, Buffalo, NY 14260, USA
| | - Sergey M. Deyev
- Bionanophotonics Laboratory, Institute of Engineering Physics for Biomedicine (PhysBio), National Research Nuclear University MEPhI (Moscow Engineering Physics Institute), Kashirskoe Shosse 31, 115409 Moscow, Russia; (G.V.T.); (M.S.S.); (P.V.S.); (J.S.B.); (A.A.P.); (S.M.K.); (P.N.P.); (S.M.D.)
- Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Russian Academy of Sciences, 117997 Moscow, Russia;
- “Biomarker” Research Laboratory, Institute of Fundamental Medicine and Biology, Kazan Federal University, 18 Kremlyovskaya St., 420008 Kazan, Russia
- Institute of Molecular Theranostics, Sechenov First Moscow State Medical University, 119991 Moscow, Russia
| | | |
Collapse
|
26
|
Ahmadi M, Khoramjouy M, Dadashzadeh S, Asadian E, Mosayebnia M, Geramifar P, Shahhosseini S, Ghorbani-Bidkorpeh F. Pharmacokinetics and biodistribution studies of [99mTc]-Labeled ZIF-8 nanoparticles to pave the way for image-guided drug delivery and theranostics. J Drug Deliv Sci Technol 2023. [DOI: 10.1016/j.jddst.2023.104249] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
27
|
He Z, Xiang W, Fan Q, Wang L, Chao J. A DNA origami nanostructure embedded with NQO1-activated prodrugs for precision drug delivery. Chem Commun (Camb) 2023; 59:912-915. [PMID: 36594872 DOI: 10.1039/d2cc06367k] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
A rectangle DNA origami nanostructure equipped with doxorubicin-derived prodrugs targeting a tumor cell-specific enzyme (NQO1) is constructed. Combining the high prodrug payload of DNA origami and NQO1-activated chemotherapy, this nanosystem presents therapeutic selectivity for NQO1-overexpressing MCF-7 cells over healthy L02 cells, offering a potent strategy for precision cancer therapy.
Collapse
Affiliation(s)
- Zhimei He
- Smart Health Big Data Analysis and Location Services Engineering Research Center of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts & Telecommunications, Nanjing, 210023, P. R. China.
| | - Wenjie Xiang
- Key Laboratory for Organic Electronics & Information Displays (KLOEID), Jiangsu Key Laboratory for Biosensors Institute of Advanced Materials (IAM) and School of Materials Science and Engineering, Nanjing University of Posts & Telecommunications, Nanjing, 210023, P. R. China
| | - Qin Fan
- Key Laboratory for Organic Electronics & Information Displays (KLOEID), Jiangsu Key Laboratory for Biosensors Institute of Advanced Materials (IAM) and School of Materials Science and Engineering, Nanjing University of Posts & Telecommunications, Nanjing, 210023, P. R. China
| | - Lianhui Wang
- Key Laboratory for Organic Electronics & Information Displays (KLOEID), Jiangsu Key Laboratory for Biosensors Institute of Advanced Materials (IAM) and School of Materials Science and Engineering, Nanjing University of Posts & Telecommunications, Nanjing, 210023, P. R. China
| | - Jie Chao
- Smart Health Big Data Analysis and Location Services Engineering Research Center of Jiangsu Province, School of Geographic and Biologic Information, Nanjing University of Posts & Telecommunications, Nanjing, 210023, P. R. China. .,Key Laboratory for Organic Electronics & Information Displays (KLOEID), Jiangsu Key Laboratory for Biosensors Institute of Advanced Materials (IAM) and School of Materials Science and Engineering, Nanjing University of Posts & Telecommunications, Nanjing, 210023, P. R. China
| |
Collapse
|
28
|
Baumann V, Popa K, Walter O, Rivenet M, Senentz G, Morel B, Konings RJ. Synthesis of Nanocrystalline PuO 2 by Hydrothermal and Thermal Decomposition of Pu(IV) Oxalate: A Comparative Study. NANOMATERIALS (BASEL, SWITZERLAND) 2023; 13:340. [PMID: 36678093 PMCID: PMC9865700 DOI: 10.3390/nano13020340] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/21/2022] [Revised: 01/10/2023] [Accepted: 01/11/2023] [Indexed: 06/17/2023]
Abstract
In recent years, the hydrothermal conversion of actinide (IV) oxalates into nanometric actinide dioxides (AnO2) has begun to be investigated as an alternative to the widely implemented thermal decomposition method. We present here a comparison between the hydrothermal and the conventional thermal decomposition of Pu(IV) oxalate in terms of particle size, morphology and residual carbon content. A parametric study was carried out in order to define the temperature and time applied in the hydrothermal conversion of tetravalent Pu-oxalate into PuO2 and to optimize the reaction conditions.
Collapse
Affiliation(s)
- Viktoria Baumann
- Univ. Lille, CNRS, Centrale Lille, Univ. Artois, UMR 8181—UCCS—Unité de Catalyse et Chimie du Solide, F-59000 Lille, France
- European Commission, Joint Research Centre, 76344 Karlsruhe, Germany
| | - Karin Popa
- European Commission, Joint Research Centre, 76344 Karlsruhe, Germany
| | - Olaf Walter
- European Commission, Joint Research Centre, 76344 Karlsruhe, Germany
| | - Murielle Rivenet
- Univ. Lille, CNRS, Centrale Lille, Univ. Artois, UMR 8181—UCCS—Unité de Catalyse et Chimie du Solide, F-59000 Lille, France
| | | | | | - Rudy J.M. Konings
- European Commission, Joint Research Centre, 76344 Karlsruhe, Germany
| |
Collapse
|
29
|
Xu Y, Nie Z, Ni N, Zhang X, Yuan J, Gao Y, Gong Y, Liu S, Wu M, Sun X. Shield-activated two-way imaging nanomaterials for enhanced cancer theranostics. Biomater Sci 2022; 10:6893-6910. [PMID: 36317535 DOI: 10.1039/d2bm01317g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Smart nanomaterials with stimuli-responsive imaging enhancement have been widely developed to meet the requirements of accurate cancer diagnosis. However, these imaging nanoenhancers tend to be always on during circulation, which significantly increases the background signal when assessing the imaging performance. To improve unfavorable signal-to-noise ratios, an effective way is to shield the noise signal of these nanoprobes in non-targeted areas. Fortunately, there is a natural mutual shielding effect between some imaging nanomaterials, which provides the possibility of designing engineered nanomaterials with imaging quenching between two different components at the beginning. Once in the tumor microenvironment, the two components will present activated dual-mode imaging ability because of their separation, designated as two-way imaging tuning. This review highlights the design and mechanism of a series of engineered nanomaterials with two-way imaging tuning and their latest applications in the fields of cancer magnetic resonance imaging, fluorescence imaging, and their combination. The challenges and future directions for the improvement of these engineered nanomaterials towards clinical transformation are also discussed. This review aims to introduce the special constraint relationships of imaging components and provide scientists with simpler and more efficient nanoplatform construction ideas, promoting the development of engineered nanomaterials with two-way imaging tuning in cancer theranostics.
Collapse
Affiliation(s)
- Yang Xu
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| | - Zhaokun Nie
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| | - Nengyi Ni
- Department of Chemical and Biomolecular Engineering, National University of Singapore, Singapore 117585, Singapore
| | - Xinyu Zhang
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| | - Jia Yuan
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| | - Yuan Gao
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| | - Yufang Gong
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| | - Shuangqing Liu
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| | - Min Wu
- Functional and Molecular Imaging Key Laboratory of Sichuan Province, West China Hospital, Sichuan University, Chengdu, China.
| | - Xiao Sun
- School of Chemistry and Pharmaceutical Engineering, Medical Science and Technology Innovation Center, Shandong First Medical University & Shandong Academy of Medical Sciences, Jinan 250000, China.
| |
Collapse
|
30
|
Lindsley C, Müller CE, Bongarzone S. Diagnostic and Therapeutic Radiopharmaceuticals. ACS Pharmacol Transl Sci 2022; 5:835-837. [PMID: 36268118 PMCID: PMC9578137 DOI: 10.1021/acsptsci.2c00173] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/28/2022] [Indexed: 11/28/2022]
Affiliation(s)
- Craig
W. Lindsley
- Department
of Pharmacology, Department of Chemistry, and Vanderbilt Institute
of Chemical Biology, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - Christa E. Müller
- PharmaCenter
Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität Bonn, D-53121 Bonn, Germany
| | - Salvatore Bongarzone
- Technical
Research and Development, Advanced Accelerator
Applications, a Novartis Company, via Ribes 5, Colleretto
Giacosa 10010, Italy
| |
Collapse
|
31
|
Lindsley CW, Müller CE, Bongarzone S. Diagnostic and Therapeutic Radiopharmaceuticals. J Med Chem 2022; 65:12497-12499. [DOI: 10.1021/acs.jmedchem.2c01403] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Affiliation(s)
- Craig W. Lindsley
- Department of Pharmacology, Department of Chemistry, and Vanderbilt Institute of Chemical Biology, School of Medicine, Vanderbilt University, Nashville, Tennessee 37232, United States
| | - Christa E. Müller
- PharmaCenter Bonn, Pharmaceutical Institute, Pharmaceutical & Medicinal Chemistry, Rheinische Friedrich-Wilhelms-Universität Bonn, D-53121 Bonn, Germany
| | - Salvatore Bongarzone
- Technical Research and Development, Advanced Accelerator Applications, a Novartis Company, via Ribes 5, Colleretto Giacosa 10010, Italy
| |
Collapse
|
32
|
Caers J, Duray E, Vrancken L, Marcion G, Bocuzzi V, De Veirman K, Krasniqi A, Lejeune M, Withofs N, Devoogdt N, Dumoulin M, Karlström AE, D’Huyvetter M. Radiotheranostic Agents in Hematological Malignancies. Front Immunol 2022; 13:911080. [PMID: 35865548 PMCID: PMC9294596 DOI: 10.3389/fimmu.2022.911080] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Accepted: 06/06/2022] [Indexed: 12/23/2022] Open
Abstract
Radioimmunotherapy (RIT) is a cancer treatment that combines radiation therapy with tumor-directed monoclonal antibodies (Abs). Although RIT had been introduced for the treatment of CD20 positive non-Hodgkin lymphoma decades ago, it never found a broad clinical application. In recent years, researchers have developed theranostic agents based on Ab fragments or small Ab mimetics such as peptides, affibodies or single-chain Abs with improved tumor-targeting capacities. Theranostics combine diagnostic and therapeutic capabilities into a single pharmaceutical agent; this dual application can be easily achieved after conjugation to radionuclides. The past decade has seen a trend to increased specificity, fastened pharmacokinetics, and personalized medicine. In this review, we discuss the different strategies introduced for the noninvasive detection and treatment of hematological malignancies by radiopharmaceuticals. We also discuss the future applications of these radiotheranostic agents.
Collapse
Affiliation(s)
- Jo Caers
- Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium
- Department of Hematology, CHU de Liège, Liège, Belgium
- *Correspondence: Jo Caers,
| | - Elodie Duray
- Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium
- Centre for Protein Engineering, Inbios, University of Liège, Liège, Belgium
| | - Louise Vrancken
- Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium
- Department of Hematology, CHU de Liège, Liège, Belgium
| | - Guillaume Marcion
- Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium
| | - Valentina Bocuzzi
- Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium
| | - Kim De Veirman
- Department of Hematology and Immunology, Vrije Universiteit Brussel, Brussels, Belgium
| | - Ahmet Krasniqi
- Laboratory of In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium
| | - Margaux Lejeune
- Laboratory of Hematology, GIGA I³, University of Liège, Liège, Belgium
| | - Nadia Withofs
- Department of Nuclear Medicine, CHU de Liège, Liège, Belgium
| | - Nick Devoogdt
- Laboratory of In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium
| | - Mireille Dumoulin
- Centre for Protein Engineering, Inbios, University of Liège, Liège, Belgium
| | - Amelie Eriksson Karlström
- Department of Protein Science, School of Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology, Stockholm, Sweden
| | - Matthias D’Huyvetter
- Laboratory of In Vivo Cellular and Molecular Imaging Laboratory (ICMI), Vrije Universiteit Brussel, Brussels, Belgium
| |
Collapse
|